Immunocore Holdings financials
$30.85+0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $115.9M | $106.7M | $104.5M | $103.7M | $98.0M | $93.9M | $84.1M | $80.2M | $75.4M | $70.5M | $70.2M | $64.8M |
| Gross profit | $114.8M | $106.2M | $101.8M | $103.2M | $96.9M | $93.0M | $83.7M | $79.8M | $73.7M | $70.3M | $70.0M | $64.6M |
| Gross margin | 99.1% | 99.6% | 97.4% | 99.5% | 98.9% | 99.1% | 99.6% | 99.4% | 97.7% | 99.7% | 99.7% | 99.6% |
| Operating income | -$3.0M | $7.3M | -$19.7M | -$7.2M | -$14.9M | -$3.6M | -$19.5M | -$8.5M | -$16.0M | -$26.5M | -$17.1M | -$14.1M |
| Net income | -$808.0K | $13.0M | -$30.1M | -$177.0K | -$10.3M | $5.0M | -$23.8M | $8.7M | -$11.6M | -$24.4M | -$19.7M | $906.0K |
| Net margin | −0.7% | 12.2% | −28.8% | −0.2% | −10.5% | 5.4% | −28.3% | 10.9% | −15.4% | −34.7% | −28.1% | 1.4% |
| Diluted EPS | $-0.02 | $0.25 | $-0.62 | $0.00 | $-0.20 | $0.10 | $-0.50 | $0.17 | $-0.23 | $-0.49 | $-0.44 | $0.02 |
| EBITDA | -$2.0M | $8.2M | -$18.9M | -$6.4M | -$14.1M | -$2.8M | -$18.3M | -$7.5M | -$15.0M | -$25.5M | -$17.1M | -$13.1M |
| Operating cash flow | $15.9M | -$13.8M | -$32.7M | -$4.5M | $26.0M | $435.0K | -$14.0M | $21.1M | $23.5M | -$4.6M | -$17.7M | $10.1M |
| Free cash flow | $15.1M | -$15.6M | -$35.5M | -$5.2M | $25.6M | $137.0K | -$17.5M | $20.3M | $23.1M | -$5.0M | -$18.6M | $9.9M |
| Diluted shares | 51.0M | 52.9M | 48.7M | 50.4M | 50.3M | 51.9M | 47.3M | 52.8M | 50.0M | 49.9M | 44.5M | 54.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $484.9M | $452.7M | $467.7M | $498.4M | $487.9M | $476.8M |
| Short-term investments | $395.3M | $392.2M | $396.4M | $393.9M | $394.9M | $360.2M |
| Total debt | $394.2M | $393.7M | $393.1M | $392.6M | $392.1M | $391.5M |
| Total assets | $1.12B | $1.07B | $1.07B | $1.10B | $1.08B | $1.03B |
| Total liabilities | $699.6M | $678.4M | $686.2M | $705.9M | $693.9M | $649.5M |
| Shareholders' equity | $419.8M | $393.7M | $381.0M | $396.6M | $388.5M | $378.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology